Laurent Lecanu, MSc, PhD

Primary Axis: 
Neurosciences
Research Focus: 

Research focuses on developing neuroprotective and brain repair strategies for neurodegenerative diseases, in particular Alzheimer’s disease, and other neurological conditions like brain stroke and traumatic brain injury. Approaches aim at the modification of the neurosteroid homeostasis, neurogenesis, oxidative stress and bioenergetic of the brain cells. Development of Alzheimer’s disease non-transgenic animal models to help understand the pathology of the disease and to have a screening tool relevant to our research. Studies also include the gender- and age-based differences of neural stem cells neurogenesis potential to address the issue of tailoring neural stem cell grafting to each patient. In order to meet the needs of our drug development program and of our more fundamental research we use various animal models and in vivo technologies, cell lines, primary cultures and isolated mitochondria, and computer-assisted drug design (molecular modeling and in silico screening).Drug Development, neuropharmacology, neurosteroids, Alzheimer’s disease, neurodegenerative disease, brain repair therapy, neural stem cells.

Keywords: 
Drug Development, neuropharmacology, neurosteroids, Alzheimer’s disease, neurodegenerative disease, brain repair therapy, neural stem cells.
Location: 
Royal Victoria Hospital
Publications:
Lecanu L, Papadopoulos V. Cutting-edge patents in Alzheimer’s disease drug discovery: anticipation of potential future treatments. Recent Patents on CNS Drug Discovery, 2: 113-123; 2007.
Lecanu L, Greeson J, Papadopoulos V. Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Pharmacology 76: 19-33; 2006.
Lecanu L, Yao W, Piechot A, Greeson J, Tzalis D, Papadopoulos V. Identification, design, synthesis, and pharmacological activity of (4-ethyl-piperazin-1-yl)-phenylmethanone derivatives with neuroprotective properties against -amyloid-induced toxicity. Neuropharmacology 49: 86-96; 2005.

News Releases

MUHC study identifies procedure that detects early stages. New blood test that will diagnose Alzheimer’s disease may soon hit the market.

... read more